Latest Expert Opinions

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
July 10, 2018

She views it as a growth stock. They acquire chains in the US and outside North America and are very good at fitting them in. They are very good operators. Traffic at its stores has been muted for the past few years. She would prefer to be in a sector that has strong inherent growth rather than growth by acquisition. This provides a tailwind rather than the headwind faced by companies like Couche-Tard. (Analysts’ price target is $73.64)

She views it as a growth stock. They acquire chains in the US and outside North America and are very good at fitting them in. They are very good operators. Traffic at its stores has been muted for the past few years. She would prefer to be in a sector that has strong inherent growth rather than growth by acquisition. This provides a tailwind rather than the headwind faced by companies like Couche-Tard. (Analysts’ price target is $73.64)

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management
Price
$60.800
Owned
No
TOP PICK
TOP PICK
July 10, 2018

The stock popped a little bit with the approval of their Line 3 project. The route is not yet settled but the process is clear. They are simplifying their corporate structure. They are planning to sell about $10 billion of noncore assets to pay down debt and have announced sales of over $7 billion, which is $4 billion ahead of schedule. They expect to grow the dividend by 10% until 2020, andcash flow will grow with this because Line 3 will come online in late 2019. (Analysts’ price target is $52.99)

Enbridge (ENB-T)
July 10, 2018

The stock popped a little bit with the approval of their Line 3 project. The route is not yet settled but the process is clear. They are simplifying their corporate structure. They are planning to sell about $10 billion of noncore assets to pay down debt and have announced sales of over $7 billion, which is $4 billion ahead of schedule. They expect to grow the dividend by 10% until 2020, andcash flow will grow with this because Line 3 will come online in late 2019. (Analysts’ price target is $52.99)

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management
Price
$46.950
Owned
Yes
TOP PICK
TOP PICK
July 10, 2018

They gave a lot of clarity on their legacy products at their Investor Day last week. They are expanding other parts of the business to drive down the impact of legacy businesses on their overall income. Their new CEO used to run Manulife Asia, which is very high growth. Their PE multiple of 9x is very low compared to Sun Life’s 12x. Their target ROE is 13% and they achieved that in the first quarter. The company’s Price to Earnings and Price to Book will rise if ROE stays this high. (Analysts’ price target is $29.65)

They gave a lot of clarity on their legacy products at their Investor Day last week. They are expanding other parts of the business to drive down the impact of legacy businesses on their overall income. Their new CEO used to run Manulife Asia, which is very high growth. Their PE multiple of 9x is very low compared to Sun Life’s 12x. Their target ROE is 13% and they achieved that in the first quarter. The company’s Price to Earnings and Price to Book will rise if ROE stays this high. (Analysts’ price target is $29.65)

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management
Price
$23.860
Owned
Yes
TOP PICK
TOP PICK
July 10, 2018

Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29)

Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29)

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management
Price
$127.380
Owned
Yes
WATCH
WATCH
July 10, 2018

He's fascinated by the potential in e-sports. Everybody around the world loves videogames, even watching people play them. The problem is it's a hit and miss business, either launching a blockbuster or a dud. But he's interested and
tracking this industry closely. The runway is long.

He's fascinated by the potential in e-sports. Everybody around the world loves videogames, even watching people play them. The problem is it's a hit and miss business, either launching a blockbuster or a dud. But he's interested and
tracking this industry closely. The runway is long.

Barry Schwartz
CIO & Portfolio Manager, Baskin Wealth Management
Price
$144.190
Owned
No
BUY
BUY
July 10, 2018

Pays a 4.5% yield which is very safe. It's a mid-stream pipeline company. Oil prices rising should help them.

Keyera Corp (KEY-T)
July 10, 2018

Pays a 4.5% yield which is very safe. It's a mid-stream pipeline company. Oil prices rising should help them.

Barry Schwartz
CIO & Portfolio Manager, Baskin Wealth Management
Price
$36.850
Owned
Unknown
COMMENT
COMMENT
July 10, 2018

A Canadian software success story. He looked at it, but bought Constellation Software instead. That said, Open Text has delivered the goods.

Open Text (OTEX-T)
July 10, 2018

A Canadian software success story. He looked at it, but bought Constellation Software instead. That said, Open Text has delivered the goods.

Barry Schwartz
CIO & Portfolio Manager, Baskin Wealth Management
Price
$48.770
Owned
No